AN2 Therapeutics, Inc.
ANTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $7 | $3 | $8 | $5 |
| G&A Expenses | $3 | $4 | $4 | $3 |
| SG&A Expenses | $3 | $4 | $4 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $10 | $7 | $12 | $9 |
| Operating Income | -$10 | -$7 | -$12 | -$9 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $1 | $1 |
| Pre-Tax Income | -$9 | -$6 | -$11 | -$8 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9 | -$6 | -$11 | -$8 |
| % Margin | – | – | – | – |
| EPS | -0.31 | -0.21 | -0.35 | -0.25 |
| % Growth | -47.6% | 40% | -40% | – |
| EPS Diluted | -0.31 | -0.21 | -0.35 | -0.25 |
| Weighted Avg Shares Out | 30 | 30 | 30 | 30 |
| Weighted Avg Shares Out Dil | 30 | 30 | 30 | 30 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $9 |
| EBITDA | -$9 | -$7 | -$12 | $0 |
| % Margin | – | – | – | – |